BR112016017999A8 - Comprimido, e, formulação adequada para prensar em um comprimido - Google Patents

Comprimido, e, formulação adequada para prensar em um comprimido

Info

Publication number
BR112016017999A8
BR112016017999A8 BR112016017999A BR112016017999A BR112016017999A8 BR 112016017999 A8 BR112016017999 A8 BR 112016017999A8 BR 112016017999 A BR112016017999 A BR 112016017999A BR 112016017999 A BR112016017999 A BR 112016017999A BR 112016017999 A8 BR112016017999 A8 BR 112016017999A8
Authority
BR
Brazil
Prior art keywords
tablet
formulation suitable
squeezing
api
formula
Prior art date
Application number
BR112016017999A
Other languages
English (en)
Other versions
BR112016017999B1 (pt
BR112016017999A2 (pt
Inventor
ann johnson Mary
Resende ALLAIN Leonardo
Mark Eickhoff W
B Ikeda Craig
D Brown Chad
J Flanagan Francis Jr
NOFSINGER Rebecca
Marota Melanie
LUPTON Lisa
B Patel Paresh
XI Hanmi
Xu Wei
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53778348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016017999(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112016017999A2 publication Critical patent/BR112016017999A2/pt
Publication of BR112016017999A8 publication Critical patent/BR112016017999A8/pt
Publication of BR112016017999B1 publication Critical patent/BR112016017999B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

COMPRIMIDO, E, FORMULAÇÃO ADEQUADA PARA PRENSAR EM UM COMPRIMIDO A presente invenção está direcionada às composições compreendendo um extrusado ou solução sólida de um composto, ou um sal deste, da Fórmula I (API): a Fórmula I, em que "Ra" é independentemente -H ou -F, em uma matriz polimérica solúvel em água que também compreende um sistema de desintegração permitindo que um comprimido fabricado a partir destes desintegre rapidamente no ambiente no qual o API deve ser liberado.
BR112016017999-4A 2014-02-05 2015-01-30 Comprimido, e, formulação adequada para prensar em um comprimido BR112016017999B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461936019P 2014-02-05 2014-02-05
US61/936,019 2014-02-05
US201462087366P 2014-12-04 2014-12-04
US62/087,366 2014-12-04
PCT/US2015/013672 WO2015119848A1 (en) 2014-02-05 2015-01-30 Tablet formulation for cgrp-active compounds

Publications (3)

Publication Number Publication Date
BR112016017999A2 BR112016017999A2 (pt) 2017-08-08
BR112016017999A8 true BR112016017999A8 (pt) 2023-04-11
BR112016017999B1 BR112016017999B1 (pt) 2023-06-27

Family

ID=

Also Published As

Publication number Publication date
MX2016010169A (es) 2016-10-07
WO2015119848A1 (en) 2015-08-13
EP3102564A4 (en) 2017-10-18
RU2019123406A (ru) 2019-10-03
KR102448369B1 (ko) 2022-09-28
JP2019108366A (ja) 2019-07-04
KR20220136460A (ko) 2022-10-07
AU2019226239A1 (en) 2019-09-26
MX2021006790A (es) 2021-07-15
IL246828A0 (en) 2016-08-31
US11925709B2 (en) 2024-03-12
JP6666490B2 (ja) 2020-03-13
RU2696578C1 (ru) 2019-08-05
AU2021245229A1 (en) 2021-11-04
HK1232218A1 (zh) 2018-01-05
JP2017505306A (ja) 2017-02-16
US20210085612A1 (en) 2021-03-25
EP3102564A1 (en) 2016-12-14
IL246828B (en) 2019-05-30
SA516371613B1 (ar) 2021-06-19
US20230248655A1 (en) 2023-08-10
AU2015214502A1 (en) 2016-07-21
US10117836B2 (en) 2018-11-06
US20160346214A1 (en) 2016-12-01
BR112016017999A2 (pt) 2017-08-08
AU2023258317A1 (en) 2023-11-16
US20190209478A1 (en) 2019-07-11
JP6491669B2 (ja) 2019-03-27
AU2015214502B2 (en) 2019-06-06
CN105960397B (zh) 2020-09-04
CN112022818A (zh) 2020-12-04
AU2019226239B2 (en) 2021-07-08
KR20160113296A (ko) 2016-09-28
CN105960397A (zh) 2016-09-21
KR20230107902A (ko) 2023-07-18
CA2937315A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
SA516371613B1 (ar) Cgrp صيغة قرص لمركبات نشطة تجاه
BR112016028961A2 (pt) composições compreendendo fibras obtidas por via eletro-hidrodinâmica para administração de dosagens específicas de uma substância ativa à pele ou mucosa
BR112017013691A2 (pt) composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
BR112017010676A2 (pt) composição de concentrado de nanopartícula estável, emulsão de nanopartícula, e, método para a distribuição de um sistema de partícula de nanolipídio líquido para um alvo
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
MX2019006291A (es) Composiciones de lactato de calcio y metodos de uso.
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112015031329A2 (pt) composições compreendendo ciclodextrina e ácido hialurônico reticulado
PH12015502556A1 (en) Modified release formulation
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
MY182288A (en) Process for fractionation of oligosaccharides from agri-waste
BR112017000849A2 (pt) composição antiaderente
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
ECSP17021465A (es) Formulación que comprende glicopirrolato, método y aparato
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112013006404A2 (pt) processo para produzir grânulos, formulação, e, usos dos grânulos e dos aglomerados prensados
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
BR112016014981A2 (pt) Acelerador de produção de catecolamina e agente preventivo e terapêutico e composição alimentícia preventiva e terapêutica para doenças causadas por deficiência de catecolamina
BR112014026040A2 (pt) tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023003966-1 PROTOCOLO 870230017958 EM 02/03/2023 15:33.

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2015, OBSERVADAS AS CONDICOES LEGAIS